GlassScriptPhysician profile
Ashley A Lamb
NPI 1124274352
$8,843.81
in general payments reported to CMS, 2019-2025
19 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,180 · 2022: $1,927 · 2023: $1,997 · 2024: $2,257 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,528 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.75 |
| Education | $208.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,876.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,184.82 | 2021-2025 | |
| Janssen Biotech, INC. | $1,023.94 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $905.09 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $801.42 | 2022-2025 | Sotyktu |
| Ucb, INC. | $466.79 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $383.57 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $370.34 | 2021-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $341.39 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $337.03 | 2021-2024 | Ilumya, Absorica Ld, Winlevi |
| Incyte Corporation | $254.86 | 2021-2025 | Opzelura |
| Pfizer INC. | $254.11 | 2021-2024 | |
| Amgen INC. | $184.11 | 2021-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.42 | 2023-2024 | Cyltezo, Spevigo |
| Vyne Pharmaceuticals INC. | $96.84 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $81.66 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $46.96 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.60 | 2021-2024 | Arazlo |
| Dermavant Sciences, INC. | $31.95 | 2022-2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.